Target intelligence / Profile preview

NKG2D ligands (MICA, MICB, ULBP1-6) (NKG2DLs)

Target
NKG2DLs
Molecular classification
MHC class I-like protein, Glycoprotein, Receptor ligand
01

Overview

Stress-induced ligands on tumor cells, primarily the NKG2D ligands (MICA, MICB, and ULBP1-6), are a group of cell surface proteins that are upregulated in response to cellular stress, DNA damage, and oncogenic transformation. These ligands are recognized by the activating receptor NKG2D, which is expressed on natural killer (NK) cells, CD8+ T cells, and gamma-delta T cells. Under normal conditions, these ligands are minimally expressed, but their presence on tumor cells serves as a "kill me" signal that triggers immune-mediated destruction. However, tumors often evade this surveillance by shedding these ligands into a soluble form (sNKG2DL), which acts as a decoy and downregulates the NKG2D receptor on effector cells. Related NK-activating ligands include B7-H6 (ligand for NKp30) and PVR/CD155 (ligand for DNAM-1), which similarly signal the presence of transformed cells. Therapeutic strategies targeting this axis include NKG2D-based CAR-T cells, monoclonal antibodies that stabilize surface ligands or prevent shedding, and small molecules like HDAC inhibitors that induce ligand expression. These approaches aim to restore or enhance the innate and adaptive immune response against a wide variety of solid and hematological malignancies.

Other names
Stress-induced ligandsMHC class I polypeptide-related sequence A/BUL16-binding proteinsRAET1 familyNK-activating receptor ligandsMICAMICBULBP1ULBP2ULBP3ULBP4ULBP5ULBP6B7-H6PVRCD155
02

Mechanism of action

Drugs targeting these ligands primarily work by activating NK cells and T cells through the NKG2D receptor, preventing the proteolytic shedding of ligands from the tumor surface, or inducing the expression of these ligands using stress-mimicking agents like HDAC inhibitors.

03

Biological functions

Immune responseNK cell activationT cell co-stimulationStress responseCytotoxicity induction
04

Disease associations

CancerInfectionAutoimmune disease
05

Safety considerations

Off-tumor toxicity on stressed healthy cellsImmune evasion via sheddingReceptor downregulationCytokine release syndrome
06

Interacting drugs

CYAD-01

5 more in the full profile.

07

Biomarkers

Surface MICA/B expressionSoluble MICA/B (sMICA/B) levelsULBP expressionNKG2D receptor density

Beyond the preview

Go deeper on NKG2D ligands (MICA, MICB, ULBP1-6) (NKG2DLs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKG2D ligands (MICA, MICB, ULBP1-6) (NKG2DLs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call